Coherus Oncology, Inc. (CHRS)
1.41
-0.05
(-3.42%)
USD |
NASDAQ |
Aug 28, 16:00
1.40
-0.01
(-0.71%)
After-Hours: 20:00
Coherus Oncology EPS Diluted (Quarterly) : -0.1312 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1312 |
| March 31, 2026 | -0.2782 |
| December 31, 2025 | -0.3097 |
| September 30, 2025 | -0.3021 |
| June 30, 2025 | -0.3561 |
| March 31, 2025 | -0.4883 |
| December 31, 2024 | -0.4387 |
| September 30, 2024 | -0.0839 |
| June 30, 2024 | -0.3223 |
| March 31, 2024 | -0.4503 |
| December 31, 2023 | -0.7144 |
| September 30, 2023 | -0.4056 |
| June 30, 2023 | -0.4912 |
| March 31, 2023 | -0.9553 |
| December 31, 2022 | -0.7552 |
| September 30, 2022 | -1.114 |
| June 30, 2022 | -0.6466 |
| March 31, 2022 | -1.244 |
| December 31, 2021 | -0.5952 |
| September 30, 2021 | -0.4876 |
| June 30, 2021 | -0.3957 |
| March 31, 2021 | -2.375 |
| December 31, 2020 | 0.124 |
| September 30, 2020 | 0.3193 |
| June 30, 2020 | 0.6658 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.478 |
| December 31, 2019 | 0.5006 |
| September 30, 2019 | 0.6304 |
| June 30, 2019 | 0.323 |
| March 31, 2019 | -0.2893 |
| December 31, 2018 | -0.9193 |
| September 30, 2018 | -0.8668 |
| June 30, 2018 | -0.68 |
| March 31, 2018 | -0.74 |
| December 31, 2017 | -0.84 |
| September 30, 2017 | -1.09 |
| June 30, 2017 | -1.08 |
| March 31, 2017 | -1.54 |
| December 31, 2016 | -1.71 |
| September 30, 2016 | 1.67 |
| June 30, 2016 | -1.72 |
| March 31, 2016 | -1.67 |
| December 31, 2015 | -1.35 |
| September 30, 2015 | -1.86 |
| June 30, 2015 | -1.56 |
| March 31, 2015 | -1.22 |
| December 31, 2014 | -1.47 |
| September 30, 2014 | -1.79 |
| June 30, 2014 | -0.7786 |
| March 31, 2014 | -0.7568 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | -0.6704 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -33.35M |
| Revenue (Quarterly) | 14.31M |
| Total Expenses (Quarterly) | 47.65M |
| Enterprise Value | 166.67M |
| Gross Profit Margin (Quarterly) | 64.33% |
| Profit Margin (Quarterly) | -233.1% |
| Earnings Yield | -72.43% |
| Normalized Earnings Yield | -71.52 |